The impact of immunotherapy on overall survival in patients with brain metastases


  • Immunotherapy in combination with radiotherapy increased overall survival (OS) for patients with solid cancers and brain metastases who had received definitive surgery at the primary tumor site.

Why this matters ?

  • In the setting of brain metastasis, the median survival time ranges from 4 to 16 months depending on primary tumor type.

  • Monoclonal antibody immunotherapies are a promising treatment for brain metastases, due to their ability to cross the blood–brain barrier; however, in-depth studies of immunotherapies has been limited so far.

  • It was hypothesized that patients with brain metastases who had received primary tumor resection, thereby having had the bulk of tumor mass removed, would respond better to immunotherapies.